Basis of Presentation - Additional Information (Details)
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
Nov. 02, 2020
USD ($)
$ / shares
shares
|
Oct. 31, 2020
USD ($)
$ / shares
shares
|
Oct. 27, 2020
USD ($)
$ / shares
shares
|
Oct. 22, 2020
$ / shares
shares
|
Jul. 02, 2020
$ / shares
shares
|
Jun. 05, 2020
$ / shares
shares
|
Jun. 03, 2020
USD ($)
$ / shares
shares
|
Apr. 30, 2020
USD ($)
|
Jan. 21, 2020
USD ($)
Debtinstrument
$ / shares
shares
|
Jun. 30, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2019
USD ($)
|
Sep. 30, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
$ / shares
shares
|
Sep. 08, 2020
USD ($)
|
Jul. 16, 2019
USD ($)
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description of deferring payment on US payroll taxes |
|
|
|
|
|
|
|
|
|
|
|
|
In April 2020, the Company began deferring payment on its share of U.S. payroll taxes owed, as allowed by the Coronavirus Aid, Relief and Economic Security Act (CARES Act) through December 31, 2020. The Company is able to defer half of its share of U.S. payroll taxes owed until December 31, 2021, with the remaining half due on December 31, 2022
|
|
|
|
|
| Ordinary shares, shares issued | shares |
|
|
|
|
|
|
|
|
|
|
21,239,093
|
|
21,239,093
|
|
14,868,973
|
|
|
| Ordinary shares, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
$ 0.01
|
|
|
| Proceeds from registered direct offerings, net of transaction costs |
|
|
|
|
|
|
|
|
|
|
|
|
$ 8,560,000
|
|
|
|
|
| Net losses |
|
|
|
|
|
|
|
|
|
|
$ 12,199,000
|
$ 31,271,000
|
40,820,000
|
$ 79,489,000
|
$ 103,130,000
|
|
|
| Accumulated deficit |
|
|
|
|
|
|
|
|
|
|
$ 275,743,000
|
|
$ 275,743,000
|
|
$ 234,923,000
|
|
|
| June 3 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
|
|
|
| June 30 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
|
|
|
| Iterum Therapeutics US Limited | Silicon Valley Bank (SVB) | Paycheck Protection Program |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
$ 744,000
|
|
|
|
|
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
|
|
|
|
1.00%
|
|
|
|
|
|
|
|
|
|
| Debt instrument maturity period |
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
| Minimum percentage of loan proceeds used for payroll costs |
|
|
|
|
|
|
|
60.00%
|
|
|
|
|
|
|
|
|
|
| Debt instrument, description |
|
|
|
|
|
|
|
Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for U.S. payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for U.S. payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks following April 30, 2020, and has requested forgiveness for a portion of the PPP loan from the Lender
|
|
|
|
|
Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the note on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks from April 30, 2020, and has requested forgiveness for a portion of the loan from the Lender
|
|
|
|
|
| Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate initial offering price of securities authorized to issue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 150,000,000
|
| Private Placement and Rights Offering | 2025 Exchangeable Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
$ 51,800,000
|
|
|
|
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
|
|
|
|
|
6.50%
|
|
|
|
|
|
|
|
|
| Private Placement and Rights Offering | RLNs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
| Private Placement | June 3 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
|
208,023
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
$ 2.1031
|
$ 1.62
|
|
|
|
|
|
|
|
|
|
|
| Warrants expiry date |
|
|
|
|
|
Jun. 03, 2025
|
Dec. 05, 2025
|
|
|
|
|
|
|
|
|
|
|
| Warrants closing date |
|
|
|
|
|
|
Jun. 05, 2020
|
|
|
|
|
|
|
|
|
|
|
| Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement | June 30 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
236,088
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
$ 1.8531
|
|
|
|
|
$ 1.42
|
|
|
|
|
|
|
|
| Warrants expiry date |
|
|
|
|
Jun. 30, 2025
|
|
|
|
|
Jan. 02, 2026
|
|
|
|
|
|
|
|
| Warrants closing date |
|
|
|
|
|
|
|
|
|
Jul. 02, 2020
|
|
|
|
|
|
|
|
| Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement | Maximum | June 3 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
|
|
1,485,885
|
|
|
|
|
|
|
|
|
|
|
| Private Placement | Maximum | June 30 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
|
|
|
|
|
1,686,343
|
|
|
|
|
|
|
|
| Private Placement | 2025 Exchangeable Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
51,600,000
|
|
|
|
|
|
|
|
|
| Debt instrument price per unit |
|
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
| Private Placement | RLNs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
| Number of debt instruments within each notes | Debtinstrument |
|
|
|
|
|
|
|
|
50
|
|
|
|
|
|
|
|
|
| Debt instrument, aggregate potential payment capped value |
|
|
|
|
|
|
|
|
$ 160,000
|
|
|
|
|
|
|
|
|
| Debt instrument, aggregate potential payment capped rate |
|
|
|
|
|
|
|
|
4,000 times
|
|
|
|
|
|
|
|
|
| Private Placement | Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
|
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| Private Placement | Securities | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
1,286.1845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum subscription units to be accepted | shares |
|
|
|
|
|
|
|
|
220
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | 2025 Exchangeable Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
| Debt instrument price per unit |
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| Debt instrument price per unit |
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
|
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, exchange price | $ / shares |
|
|
|
|
|
|
|
|
$ 1.00
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | 2025 Exchangeable Notes | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
1,286.1845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, exchange price | $ / shares |
$ 0.7775
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | RLNs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20,000
|
|
| Number of debt instruments within each notes | Debtinstrument |
|
|
|
|
|
|
|
|
50
|
|
|
|
|
|
|
|
|
| Debt instrument, aggregate potential payment capped value |
|
|
|
|
|
|
|
|
$ 160,000
|
|
|
|
|
|
|
|
|
| Debt instrument, aggregate potential payment capped rate |
|
|
|
|
|
|
|
|
4,000 times
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | RLNs | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, percentage of net revenue from domestic sale for potential aggregate payments |
|
|
|
|
|
|
|
|
15.00%
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | RLNs | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, percentage of net revenue from domestic sale for potential aggregate payments |
|
|
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
|
|
|
| Rights Offering in Connection with Private Placement | Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from sales of securities |
|
|
|
|
|
|
|
|
$ 45,000,000
|
|
|
|
|
|
|
|
|
| Direct Offering | June 3 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, shares issued | shares |
|
|
|
|
|
|
2,971,770
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, par value | $ / shares |
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per share | $ / shares |
|
|
|
|
|
|
$ 1.6825
|
|
|
|
|
|
|
|
|
|
|
| Aggregate gross proceeds from ordinary shares |
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from registered direct offerings, net of transaction costs |
|
|
|
|
|
|
$ 4,300,000
|
|
|
|
|
|
|
|
|
|
|
| Direct Offering | June 30 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, shares issued | shares |
|
|
|
|
|
|
|
|
|
3,372,686
|
|
|
|
|
|
|
|
| Ordinary shares, par value | $ / shares |
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
|
| Purchase price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 1.4825
|
|
|
|
|
|
|
|
| Aggregate gross proceeds from ordinary shares |
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
| Proceeds from registered direct offerings, net of transaction costs |
|
|
|
|
|
|
|
|
|
$ 4,200,000
|
|
|
|
|
|
|
|
| October Offering | Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description of purchase agreement |
|
|
|
|
|
|
|
|
|
|
|
|
In connection with the October Offering, the Company entered into a Securities Purchase Agreement (the Purchase Agreement) on October 22, 2020 with certain institutional investors. The Purchase Agreement contains customary representations and warranties of the Company, termination rights of the parties, and certain indemnification obligations of the Company and ongoing covenants of the Company, including a prohibition on issuance of ordinary shares or securities convertible or exchangeable into ordinary shares by the Company for a period of 45 days after the closing of the October Offering and a prohibition on the Company entering into variable rate transactions for a period of 12 months after the closing of the October Offering, subject to certain exceptions.
|
|
|
|
|
| October Offering | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, shares issued | shares |
|
|
15,511,537
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, par value | $ / shares |
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate gross proceeds from ordinary shares |
|
|
$ 17,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from registered direct offerings, net of transaction costs |
|
$ 60,000
|
$ 15,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
$ 0.8125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants expiry date |
|
Oct. 22, 2025
|
Oct. 27, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of ordinary shares issued to purchase warrants |
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| October Offering | Subsequent Event | Pre-Funded Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ordinary shares, par value | $ / shares |
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per share | $ / shares |
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from registered direct offerings, net of transaction costs |
|
$ 60,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
6,284,615
|
11,411,539
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
$ 0.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of ordinary share at election of purchaser |
|
|
9.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| October Offering | Subsequent Event | Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per share | $ / shares |
|
|
$ 0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
1,884,615
|
20,192,307
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
$ 0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants expiry date |
|
|
Oct. 27, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| October Offering | Subsequent Event | Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
1,884,615
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
$ 0.8125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants expiry date |
|
|
|
Oct. 22, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of ordinary shares issued to purchase warrants |
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| October Offering | Minimum | Subsequent Event | Pre-Funded Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of outstanding ordinary shares |
|
|
4.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|